IL11 | Interleukin 11 | Cancer-related genes Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
IL22 | Interleukin 22 | Predicted secreted proteins
| | | | | Tissue enhanced |
IL4I1 | Interleukin 4 induced 1 | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
IL7R | Interleukin 7 receptor | Cancer-related genes CD markers Disease related genes Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ITGAX | Integrin, alpha X (complement component 3 receptor 4 subunit) | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
JAK3 | Janus kinase 3 | Cancer-related genes Cytoskeleton related proteins Disease related genes Enzymes FDA approved drug targets Predicted intracellular proteins
| | | | | Tissue enhanced |
LILRA1 | Leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 1 | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
LILRA5 | Leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 5 | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
LILRA6 | Leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 6 | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
LILRB1 | Leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1 | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
LILRB2 | Leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 2 | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
LILRB3 | Leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 3 | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
MADCAM1 | Mucosal vascular addressin cell adhesion molecule 1 | Predicted membrane proteins
| | | | | Tissue enhanced |
MARCO | Macrophage receptor with collagenous structure | Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
MEFV | Mediterranean fever | Disease related genes Predicted intracellular proteins
| | | | | Tissue enhanced |
MMP12 | Matrix metallopeptidase 12 (macrophage elastase) | Cancer-related genes Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
MMP25 | Matrix metallopeptidase 25 | Enzymes FDA approved drug targets Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |
NLRC4 | NLR family, CARD domain containing 4 | Plasma proteins Predicted intracellular proteins
| | | | | Tissue enhanced |
NOXO1 | NADPH oxidase organizer 1 | FDA approved drug targets Predicted intracellular proteins
| | | | | Tissue enhanced |
PI15 | Peptidase inhibitor 15 | Predicted secreted proteins
| | | | | Tissue enhanced |
PROK2 | Prokineticin 2 | Disease related genes Predicted secreted proteins
| | | | | Tissue enhanced |
RP13-512J5.1 | Uncharacterized protein {ECO:0000313|Ensembl:ENSP00000440272} | Predicted intracellular proteins
| | | | | Tissue enhanced |
SAMSN1 | SAM domain, SH3 domain and nuclear localization signals 1 | Predicted intracellular proteins
| | | | | Tissue enhanced |
SH2D2A | SH2 domain containing 2A | Predicted intracellular proteins
| | | | | Tissue enhanced |
SIGLEC10 | Sialic acid binding Ig-like lectin 10 | Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
SIGLEC14 | Sialic acid binding Ig-like lectin 14 | Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
SIGLEC5 | Sialic acid binding Ig-like lectin 5 | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
SIGLEC9 | Sialic acid binding Ig-like lectin 9 | Predicted membrane proteins
| | | | | Tissue enhanced |
SIRPB2 | Signal-regulatory protein beta 2 | Predicted membrane proteins
| | | | | Tissue enhanced |
THBS1 | Thrombospondin 1 | Cancer-related genes Candidate cardiovascular disease genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
TLR2 | Toll-like receptor 2 | CD markers FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
TLR8 | Toll-like receptor 8 | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
TNFAIP6 | Tumor necrosis factor, alpha-induced protein 6 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
TNFRSF10C | Tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain | Cancer-related genes CD markers Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
TNFRSF6B | Tumor necrosis factor receptor superfamily, member 6b, decoy | Predicted secreted proteins
| | | | | Tissue enhanced |
TNIP3 | TNFAIP3 interacting protein 3 | Predicted intracellular proteins
| | | | | Tissue enhanced |
TREM1 | Triggering receptor expressed on myeloid cells 1 | CD markers Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
VCAN | Versican | Disease related genes Plasma proteins Predicted intracellular proteins Predicted secreted proteins
| | | | | Tissue enhanced |